Vor Biopharma Inc. has announced new 48-week open-label extension data from a Phase 3 clinical study in China evaluating telitacicept for patients with generalized myasthenia gravis (gMG). The results, presented at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting on October 29, 2025, indicate that telitacicept demonstrated sustained efficacy and a favorable safety profile. In the study, 100% of patients treated with telitacicept for 48 weeks achieved a ≥2-point improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL), with a mean reduction of 7.5 points. The global Phase 3 trial of telitacicept is currently enrolling participants across 14 countries.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vor Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9563984-en) on October 29, 2025, and is solely responsible for the information contained therein.